A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets. New research into the pathogenesis of myelodysplastic syndromes (MDS) may help aid the ...

In PV and ET, MDS risk remains lower than AML risk but increases progressively with advancing attained age. Transformation to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in ...

Nearly 25 years after arriving at Fred Hutch Cancer Center for his hematology-oncology fellowship, Bart Scott, MD, has been named the Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair, ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Myelodysplastic syndrome is an extremely heterogeneous disease, and there is no definitive cure, so these investigators wanted a better understanding of patients’ priorities regarding their care, ...

Myelodysplastic syndromes (MDS) are treated based on type and risk assessment, but traditional therapies may not work for everyone. Clinical trials offer a way to explore emerging treatments and ...

Smokers with myelodysplastic syndromes (MDS) or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows. The study also found that heavier smokers ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “It looks like, in the low-risk [myelodysplastic ...

Myelodysplastic syndromes (MDS) and autoimmune conditions can overlap, and each may raise the risk of the other. Up to 30% of people with MDS also have an autoimmune disorder. Autoimmune conditions ...